title: Phosphorus-32 radiopharmaceuticals for the treatment of painful osseous metastases.
abstract: Phosphorus-32, employed as the orthophosphate or polyphosphate, can reduce or relieve the pain of osteoblastic metastases without serious hematologic toxicity, especially if used as a single injection. Uptake of this beta-emitter by osteoblastic-reactive bone and possibly by tumor and other cells can lead to pain reduction and often to cell killing. Efficacy has been demonstrated for the treatment of pain in 84% of 322 breast cancer patients and 77% of 444 prostate cancer patients found in a review of the literature. These results match those of the newer radiopharmaceuticals currently under investigation.
authors.affiliation: University of Cincinnati Medical Center, OH 45267.
authors.forename: E B
authors.initials: EB
authors.lastname: Silberstein
authors.forename: A H
authors.initials: AH
authors.lastname: Elgazzar
authors.forename: A
authors.initials: A
authors.lastname: Kapilivsky
mesh_terms: D001859:Bone Neoplasms / Q000503:physiopathology / Q000556:secondary*; D006801:Humans; D010146:Pain / Q000209:etiology / Q000532:radiotherapy*; D010761:Phosphorus Radioisotopes / Q000627:therapeutic use*
chemical_list: D010761:Phosphorus Radioisotopes